Temat: "Midazolam" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: A "middle-out approach" for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models.
Autorzy:: Yau E; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK.; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Gertz M; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Ogungbenro K; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK.
Aarons L; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester, UK.
Olivares-Morales A; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Mar; Vol. 12 (3), pp. 346-359. Date of Electronic Publication: 2023 Jan 31.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Midazolam*/pharmacokinetics
Diazepam*/pharmacokinetics
Humans ; Rats ; Animals ; Kinetics ; Models, Biological ; Haplorhini

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants.
Autorzy:: Boinpally R; AbbVie Inc, Madison, New Jersey, USA.
McGeeney D; AbbVie Inc, North Chicago, Illinois, USA.
Kaczynski E; AbbVie Inc, Madison, New Jersey, USA.
Weissman D; AbbVie Inc, Madison, New Jersey, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Nov; Vol. 11 (11), pp. 1341-1348. Date of Electronic Publication: 2022 Aug 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Midazolam*/adverse effects
Midazolam*/pharmacokinetics
Cytochrome P-450 CYP3A*
Adult ; Humans ; Healthy Volunteers ; Phenylalanine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects.
Autorzy:: Kropeit D; AiCuris Anti-infective Cures AG, Wuppertal, Germany.
McCormick D; AiCuris Anti-infective Cures AG, Wuppertal, Germany.; Current address: DMPK Solutions Ltd., Nottingham, Nottinghamshire, UK.
Erb-Zohar K; clinphase®, Schotten, Germany.
Stobernack HP; AiCuris Anti-infective Cures AG, Wuppertal, Germany.
Zimmermann H; AiCuris Anti-infective Cures AG, Wuppertal, Germany.
Rübsamen-Schaeff H; AiCuris Anti-infective Cures AG, Wuppertal, Germany.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Jan; Vol. 11 (1), pp. 16-24. Date of Electronic Publication: 2021 Oct 29.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Midazolam*/administration & dosage
Midazolam*/adverse effects
Midazolam*/pharmacokinetics
Acetates ; Area Under Curve ; Drug Interactions ; Female ; Healthy Volunteers ; Humans ; Quinazolines

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Old Is (Not) Gold: Midazolam Monotherapy versus Midazolam Plus Fentanyl for Sedation during Cardiac Catheterization.
Autorzy:: Black W; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Baljepally R; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Shali L; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Alsharif O; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Warden S; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Heidel E; University of Tennessee Medical Center, Heart Lung Vascular Institute, Department of Cardiology, Knoxville, TN, USA.
Zhao X; Department of Mechanical, Aerospace, and Biomedical Engineering, University of Tennessee, Knoxville, TN, USA.; Pokaż więcej
Źródło:: Journal of interventional cardiology [J Interv Cardiol] 2021 Aug 02; Vol. 2021, pp. 9932171. Date of Electronic Publication: 2021 Aug 02 (Print Publication: 2021).
Typ publikacji:: Journal Article; Randomized Controlled Trial
MeSH Terms:: Cardiac Catheterization*/adverse effects
Fentanyl*/adverse effects
Hypnotics and Sedatives*/adverse effects
Midazolam*/adverse effects
Aged ; Conscious Sedation/adverse effects ; Female ; Humans ; Male ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
Autorzy:: Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Ramsden D; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Zhang L; Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Michon I; Certara, Sheffield, UK.
Leifke E; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Smith N; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.
Jones HM; Certara, Sheffield, UK.
Scarpignato C; United Campus of Malta, Msida, Malta.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.
Typ publikacji:: Journal Article
MeSH Terms:: Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics
Cytochrome P-450 CYP3A Inducers*/pharmacokinetics
Humans ; Midazolam/pharmacokinetics ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Models, Biological

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial.
Autorzy:: Domínguez-Rodríguez A; Department of Cardiology, Hospital Universitario de Canarias, Universidad Europea de Canarias, Tenerife, Spain.; CIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Suero-Mendez C; Hospital de la Axarquía, Málaga, Spain.
Burillo-Putze G; Emergency Department, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain.
Gil V; Emergency Department, Hospital Clinic, Barcelona, Institut d'Investigació Biomèdica August Pi iSunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Calvo-Rodriguez R; Emergency Department, Hospital Universitario Reina Sofia, Córdoba, Spain.
Piñera-Salmeron P; Emergency Department, Hospital General Universitario Reina Sofía, Murcia, Spain.
Llorens P; Emergency Department, Short-Stay Unit and Home Hospitalization, Hospital General de Alicante, Alicante, Spain.
Martín-Sánchez FJ; Emergency Department, Hospital Clínico San Carlos, Universidad Complutense, Madrid, Spain.
Abreu-Gonzalez P; Department of Physiology, Facultad de Medicina, Universidad de La Laguna, Tenerife, Spain.
Miró Ò; Emergency Department, Hospital Clinic, Barcelona, Institut d'Investigació Biomèdica August Pi iSunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.; Pokaż więcej
Corporate Authors:: MIMO (MIdazolam versus MOrphine) Trial Investigators
Źródło:: European journal of heart failure [Eur J Heart Fail] 2022 Oct; Vol. 24 (10), pp. 1953-1962. Date of Electronic Publication: 2022 Jul 16.
Typ publikacji:: Randomized Controlled Trial; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Pulmonary Edema*/drug therapy
Pulmonary Edema*/etiology
Heart Failure*/drug therapy
Humans ; Adolescent ; Midazolam/therapeutic use ; Midazolam/adverse effects ; Morphine/therapeutic use ; Hospital Mortality

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Autorzy:: Britz H; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Hanke N; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Volz AK; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
Spigset O; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway.
Schwab M; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.; Department of Pharmacy and Biochemistry, University Tübingen, Tübingen, Germany.
Eissing T; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Wendl T; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Frechen S; Clinical Pharmacometrics, Bayer AG, Leverkusen, Germany.
Lehr T; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 May; Vol. 8 (5), pp. 296-307. Date of Electronic Publication: 2019 Mar 13.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Caffeine/*pharmacokinetics
Cytochrome P-450 CYP1A2/*metabolism
Fluvoxamine/*pharmacokinetics
Midazolam/*pharmacokinetics
Rifampin/*pharmacokinetics
Theophylline/*pharmacokinetics
Administration, Oral ; Algorithms ; Area Under Curve ; Caffeine/administration & dosage ; Caffeine/chemistry ; Cytochrome P-450 CYP1A2/chemistry ; Cytochrome P-450 CYP3A/chemistry ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Fluvoxamine/administration & dosage ; Fluvoxamine/chemistry ; Humans ; Midazolam/administration & dosage ; Midazolam/chemistry ; Models, Biological ; Models, Molecular ; Rifampin/administration & dosage ; Rifampin/chemistry ; Theophylline/administration & dosage ; Theophylline/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Drug-Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379 (Bersacapavir).
Autorzy:: Vandenbossche J; Janssen Pharmaceutica NV, Beerse, Belgium.
Yogaratnam J; Janssen Research & Development, South San Francisco, California, USA.
Hillewaert V; Janssen Pharmaceutica NV, Beerse, Belgium.
Rasschaert F; Janssen Pharmaceutica NV, Beerse, Belgium.
Talloen W; Janssen Pharmaceutica NV, Beerse, Belgium.
Biewenga J; Janssen Pharmaceutica NV, Beerse, Belgium.
Snoeys J; Janssen Pharmaceutica NV, Beerse, Belgium.
Kakuda TN; Janssen Research & Development, South San Francisco, California, USA.
Palmer M; Janssen Research & Development, Spring House, Pennsylvania, USA.
Nangosyah J; Janssen Pharmaceutica NV, Beerse, Belgium.
Biermer M; Janssen Pharmaceutica NV, Beerse, Belgium.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Dec; Vol. 11 (12), pp. 1419-1429. Date of Electronic Publication: 2022 Sep 05.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Hepatitis B virus*/metabolism
Adult ; Female ; Humans ; Antiviral Agents/adverse effects ; Capsid/metabolism ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Ethinyl Estradiol/pharmacology ; Itraconazole/pharmacokinetics ; Midazolam/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice? Letter regarding the article 'Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial'.
Autorzy:: Neto Gonçalves T; Internal Medicine Department, Hospital da Luz Lisboa, Lisbon, Portugal.; Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.
Margarida Andrade M; Internal Medicine Department, Hospital de Cascais, Dr. José de Almeida, Cascais, Portugal.; Pokaż więcej
Źródło:: European journal of heart failure [Eur J Heart Fail] 2022 Dec; Vol. 24 (12), pp. 2392-2393. Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:: Randomized Controlled Trial; Multicenter Study; Letter; Comment
MeSH Terms:: Heart Failure*
Pulmonary Edema*/drug therapy
Pulmonary Edema*/etiology
Humans ; Morphine/therapeutic use ; Midazolam ; Acute Disease

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Supervised Multidimensional Item Response Theory Modeling of Pediatric Iatrogenic Withdrawal Symptoms.
Autorzy:: Goulooze SC; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Ista E; Intensive Care and Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
van Dijk M; Intensive Care and Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Hankemeier T; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.
Tibboel D; Intensive Care and Pediatric Surgery, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Knibbe CAJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.
Krekels EHJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Dec; Vol. 8 (12), pp. 904-912. Date of Electronic Publication: 2019 Oct 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Fentanyl/*administration & dosage
Midazolam/*administration & dosage
Morphine/*administration & dosage
Substance Withdrawal Syndrome/*drug therapy
Substance Withdrawal Syndrome/*nursing
Child ; Child, Preschool ; Drug Therapy, Combination ; Female ; Fentanyl/therapeutic use ; Humans ; Iatrogenic Disease ; Infant ; Infant, Newborn ; Male ; Midazolam/therapeutic use ; Models, Biological ; Morphine/therapeutic use ; Observational Studies as Topic ; Supervised Machine Learning ; Surveys and Questionnaires

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
Autorzy:: Treijtel N; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.
Collins C; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.
van Bruijnsvoort M; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.
Fuhr R; PAREXEL International, Berlin, Germany.
Ernault E; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.
Gangaram-Panday S; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.
Passier P; Department of Clinical Pharmacology and Exploratory Development, Astellas Pharma Europe BV, Leiden, The Netherlands.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 May; Vol. 8 (4), pp. 529-540. Date of Electronic Publication: 2019 Feb 07.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Dextromethorphan/*administration & dosage
Losartan/*administration & dosage
Midazolam/*administration & dosage
Omeprazole/*administration & dosage
Piperidines/*administration & dosage
Pyridines/*administration & dosage
Administration, Oral ; Adult ; Area Under Curve ; Cytochrome P-450 CYP2C19/metabolism ; Cytochrome P-450 CYP2C8/metabolism ; Cytochrome P-450 CYP2C9/metabolism ; Cytochrome P-450 CYP2D6/metabolism ; Dextromethorphan/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Interactions ; Female ; Humans ; Losartan/pharmacokinetics ; Male ; Midazolam/pharmacokinetics ; Middle Aged ; Omeprazole/pharmacokinetics ; Piperidines/pharmacokinetics ; Pyridines/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Autorzy:: Adeloye T; Hammersmith Medicines Research, London, England.
Sahgal O; Hammersmith Medicines Research, London, England.
Puri A; Hammersmith Medicines Research, London, England.
Warrington S; Hammersmith Medicines Research, London, England.
Endo T; Maruho Co Ltd, Kyoto, Japan.
Dennison J; Hammersmith Medicines Research, London, England.
Johnston A; Analytical Services International, St George's University of London, London, England.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2018 Nov; Vol. 7 (8), pp. 844-859. Date of Electronic Publication: 2018 Jul 25.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Cyclosporine/*pharmacokinetics
Cytochrome P-450 CYP3A/*metabolism
Midazolam/*pharmacokinetics
Oxadiazoles/*pharmacokinetics
Ritonavir/*pharmacokinetics
Adolescent ; Adult ; Cyclosporine/blood ; Cyclosporine/pharmacology ; Cytochrome P-450 CYP3A Inducers/blood ; Cytochrome P-450 CYP3A Inducers/pharmacokinetics ; Cytochrome P-450 CYP3A Inducers/pharmacology ; Cytochrome P-450 CYP3A Inhibitors/blood ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions ; Healthy Volunteers ; Humans ; Male ; Midazolam/blood ; Midazolam/pharmacology ; Middle Aged ; Oxadiazoles/blood ; Oxadiazoles/pharmacology ; Ritonavir/blood ; Ritonavir/pharmacology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.
Autorzy:: Brussee JM; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Yu H; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Krekels EHJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
de Roos B; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.
Brill MJE; Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
van den Anker JN; Intensive Care and Department of Pediatric Surgery, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.; Division of Paediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital, Basel, Switzerland.; Division of Clinical Pharmacology, Children's National Health System, Washington, DC.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK.; Simcyp Limited (A Certara Company), Sheffield, UK.
de Wildt SN; Intensive Care and Department of Pediatric Surgery, Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands.; Department of Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Knibbe CAJ; Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, The Netherlands.; Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2018 Jun; Vol. 7 (6), pp. 374-383. Date of Electronic Publication: 2018 May 10.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytochrome P-450 CYP3A/*metabolism
Intestinal Mucosa/*chemistry
Liver/*chemistry
Midazolam/*pharmacokinetics
Administration, Intravenous ; Administration, Oral ; Biological Availability ; Humans ; Infant, Premature ; Midazolam/administration & dosage ; Models, Biological ; Random Allocation

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions.
Autorzy:: Johansson S; AstraZeneca Gothenburg, Mölndal, Sweden.
Rosenbaum DP; Ardelyx Inc., Fremont, CA, USA.
Ahlqvist M; AstraZeneca Gothenburg, Mölndal, Sweden.
Rollison H; AstraZeneca R&D, Cambridge, UK.
Knutsson M; AstraZeneca Gothenburg, Mölndal, Sweden.
Stefansson B; AstraZeneca Gothenburg, Mölndal, Sweden.
Elebring M; AstraZeneca Gothenburg, Mölndal, Sweden.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2017 Sep; Vol. 6 (5), pp. 466-475. Date of Electronic Publication: 2017 Mar 16.
Typ publikacji:: Clinical Trial, Phase I; Journal Article
MeSH Terms:: Cytochrome P-450 CYP3A/*genetics
Isoquinolines/*administration & dosage
Midazolam/*administration & dosage
Sulfonamides/*administration & dosage
Adult ; Area Under Curve ; Drug Administration Schedule ; Drug Interactions ; Female ; Gene Expression Regulation/drug effects ; Humans ; Isoquinolines/pharmacokinetics ; Male ; Metabolic Clearance Rate ; Midazolam/pharmacokinetics ; Middle Aged ; Sulfonamides/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics.
Autorzy:: Lenoir C; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Niederer A; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.
Rollason V; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Desmeules JA; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Daali Y; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland.; School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Samer CF; Division of Clinical Pharmacology and Toxicology, Department of Anaesthesiology, Pharmacology, Intensive Care and Emergency Medicine, Geneva University Hospitals, Geneva, Switzerland.; Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Pokaż więcej
Źródło:: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2022 Jan; Vol. 11 (1), pp. 30-43. Date of Electronic Publication: 2021 Nov 17.
Typ publikacji:: Journal Article
MeSH Terms:: Esomeprazole/*pharmacology
Inflammation/*physiopathology
Interleukin-6/*blood
Midazolam/*pharmacokinetics
Omeprazole/*pharmacology
Cytochrome P-450 CYP2C19/drug effects ; Cytochrome P-450 CYP2C19 Inhibitors/pharmacology ; Cytochrome P-450 CYP3A/drug effects ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Down-Regulation ; Drug Interactions ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Napabucasin Drug-Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers.
Autorzy:: Dai X; Clinical Pharmacology and Drug Metabolism, Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, Massachusetts, USA.
Karol MD; Clinical Pharmacology and Drug Metabolism, Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, Massachusetts, USA.
Hitron M; Clinical Development, Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, Massachusetts, USA.
Hard ML; Clinical Pharmacology, Nuventra, Inc., Durham, North Carolina, USA.; Current address: Praxis Precision Medicines, Cambridge, Massachusetts, USA.
Goulet MT; Clinical Pharmacology, Nuventra, Inc., Durham, North Carolina, USA.; Current address: Program Management Department, KSQ Therapeutics, Cambridge, Massachusetts, USA.
McLaughlin CF; Pharmacokinetics, Nuventra, Inc., Durham, North Carolina, USA.
Brantley SJ; Clinical NCA & PK/PD, Nuventra, Inc., Durham, North Carolina, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Aug; Vol. 10 (8), pp. 824-839. Date of Electronic Publication: 2021 Jun 09.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: ATP Binding Cassette Transporter, Subfamily G, Member 2/*metabolism
Benzofurans/*administration & dosage
Cytochrome P-450 Enzyme System/*metabolism
Naphthoquinones/*administration & dosage
Neoplasm Proteins/*metabolism
Administration, Oral ; Adult ; Benzofurans/pharmacokinetics ; Bupropion/administration & dosage ; Bupropion/pharmacokinetics ; Caffeine/administration & dosage ; Caffeine/pharmacokinetics ; Dextromethorphan/administration & dosage ; Dextromethorphan/pharmacokinetics ; Drug Interactions ; Female ; Flurbiprofen/administration & dosage ; Flurbiprofen/pharmacokinetics ; Gene Expression Regulation/drug effects ; Half-Life ; Healthy Volunteers ; Humans ; Male ; Midazolam/administration & dosage ; Midazolam/pharmacokinetics ; Naphthoquinones/pharmacokinetics ; Omeprazole/administration & dosage ; Omeprazole/pharmacokinetics ; Rosuvastatin Calcium/administration & dosage ; Rosuvastatin Calcium/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor.
Autorzy:: Ripp SL; Pfizer Inc., Groton, CT, USA.
Mukherjee A; Pfizer Inc., Groton, CT, USA.
Eng H; Pfizer Inc., Groton, CT, USA.
Stock T; Pfizer Inc., Collegeville, PA, USA.
Fleishaker D; Pfizer Inc., Groton, CT, USA.
Checchio T; Pfizer Inc., Groton, CT, USA.
Tammara B; Pfizer Inc., Collegeville, PA, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2018 Mar; Vol. 7 (3), pp. 244-255. Date of Electronic Publication: 2017 Nov 07.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytochrome P-450 CYP3A/*metabolism
Midazolam/*metabolism
Organophosphates/*metabolism
Phenanthrenes/*metabolism
Prodrugs/*metabolism
Receptors, Glucocorticoid/*agonists
Receptors, Glucocorticoid/*metabolism
Drug Interactions/physiology ; Humans ; Microsomes, Liver/drug effects ; Microsomes, Liver/metabolism ; Midazolam/pharmacology ; Organophosphates/chemistry ; Organophosphates/pharmacology ; Phenanthrenes/chemistry ; Phenanthrenes/pharmacology ; Prodrugs/chemistry ; Prodrugs/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Autorzy:: Morcos PN; Roche Innovation Center, New York, NY, USA.
Cleary Y; Roche Innovation Center, Basel, Switzerland.
Guerini E; Roche Innovation Center, Basel, Switzerland.
Dall G; d3 Medicine, Parsippany, NJ, USA.
Bogman K; Roche Innovation Center, Basel, Switzerland.
De Petris L; Karolinska Institutet, Stockholm, Sweden.
Viteri S; IOR Quiron Dexeus University Hospital, Barcelona, Spain.
Bordogna W; Roche Innovation Center, Basel, Switzerland.
Yu L; Roche Innovation Center, New York, NY, USA.
Martin-Facklam M; Roche Innovation Center, Basel, Switzerland.
Phipps A; Roche Products Ltd, Welwyn, UK.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2017 May; Vol. 6 (3), pp. 280-291. Date of Electronic Publication: 2016 Sep 28.
Typ publikacji:: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
MeSH Terms:: Carbazoles/*pharmacokinetics
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Midazolam/*administration & dosage
Piperidines/*pharmacokinetics
Rifampin/*administration & dosage
Triazoles/*administration & dosage
Adult ; Anaplastic Lymphoma Kinase ; Carbazoles/administration & dosage ; Carcinoma, Non-Small-Cell Lung/genetics ; Cytochrome P-450 CYP3A/metabolism ; Dose-Response Relationship, Drug ; Female ; Humans ; Lung Neoplasms/genetics ; Male ; Midazolam/pharmacology ; Middle Aged ; Piperidines/administration & dosage ; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors ; Receptor Protein-Tyrosine Kinases/genetics ; Rifampin/pharmacology ; Treatment Outcome ; Triazoles/pharmacology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: The use of midazolam as an appetite stimulant and anxiolytic in the common marmoset (Callithrix jacchus).
Autorzy:: Herrod JA; Research Animal Resources, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Avelino JA; Research Animal Resources, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; College of Veterinary Medicine, North Caroline State University, Raleigh, NC, USA.
Schonvisky KM; Research Animal Resources, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lynch JK; Laboratory of Auditory Neurophysiology, Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Hutchinson EK; Research Animal Resources, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Izzi JM; Research Animal Resources, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Pokaż więcej
Źródło:: Journal of medical primatology [J Med Primatol] 2021 Oct; Vol. 50 (5), pp. 249-258. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:: Clinical Trial, Veterinary; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-Anxiety Agents*/pharmacology
Veterinary Drugs*
Animals ; Appetite Stimulants ; Callithrix ; Cross-Over Studies ; Midazolam/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Autorzy:: Nebot N; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Won CS; Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.
Moreno V; START Madrid-FJD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Muñoz-Couselo E; VHIO - Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Lee DY; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Bouillaud E; Novartis Pharma AG, Basel, Switzerland.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Sep; Vol. 10 (9), pp. 1054-1063. Date of Electronic Publication: 2021 May 01.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Imidazoles/*pharmacology
Midazolam/*pharmacokinetics
Oximes/*pharmacology
Rosuvastatin Calcium/*pharmacokinetics
Adult ; Area Under Curve ; Cytochrome P-450 CYP3A/drug effects ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions ; Female ; Humans ; Imidazoles/administration & dosage ; Liver-Specific Organic Anion Transporter 1/drug effects ; Liver-Specific Organic Anion Transporter 1/metabolism ; Male ; Middle Aged ; Oximes/administration & dosage ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Solute Carrier Organic Anion Transporter Family Member 1B3/drug effects ; Solute Carrier Organic Anion Transporter Family Member 1B3/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Midazolam"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Publikacja

Język